SBIR/STTR Research Award
ANTIIDIOTYPE MAB:AN ANTIANGIOGENIC /ANTIMETASTATIC AGENT
Award amount
$122,433Program and phase
STTR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PIVOTAL BIOSCIENCES
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
Angiogenesis (new blood vessel formation) is a critical step for tumor growth and metastasis, and its inhibition is currently the most promising approach for cancer therapy. Contortrostatin (ON) is a protein isolated from southern copperhead snake venom, which has been
shown to effectively block angiogenesis, as well as metastasis. The potent
inhibitory effect of CN on cancer progression has been proven in animal models
of several types of cancer. However, two problems hinder its clinical
application. First, ON is recognized by the human immune system as a foreign
protein. Therefore, repetitive delivery of ON to patients induces the
production of antibodies that neutralize its activity. Second, ON is eliminated
from the circulation too quickly to exert a sustained effect. We propose to
circumvent these obstacles by making an antibody to the ON antibody
(antiidiotype) that will mimic the anti-cancer activity of native ON. This ON
surrogate can then be genetically modified to resemble a human antibody
(humanized), which will evade rejection by the immune system. The life span of
this 'humanized" antibody in circulation will be similar to native
immunoglobulin and thus ideal for long-term therapy. This project should result
in a biopharmaceutical lead for antiangiogenic therapy.
Technology keywords
Not reported